Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8199MR)

This product GTTS-WQ8199MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8199MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1316MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ2038MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ3740MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ3011MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ14907MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ6485MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ1195MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ1803MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADCT-402
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW